JP2024513713A5 - - Google Patents
Info
- Publication number
- JP2024513713A5 JP2024513713A5 JP2023557116A JP2023557116A JP2024513713A5 JP 2024513713 A5 JP2024513713 A5 JP 2024513713A5 JP 2023557116 A JP2023557116 A JP 2023557116A JP 2023557116 A JP2023557116 A JP 2023557116A JP 2024513713 A5 JP2024513713 A5 JP 2024513713A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- chimeric antigen
- antigen receptor
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163217P | 2021-03-19 | 2021-03-19 | |
| US63/163,217 | 2021-03-19 | ||
| PCT/IB2022/052443 WO2022195535A1 (en) | 2021-03-19 | 2022-03-17 | Chimeric antigen receptors targeting claudin-3 and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513713A JP2024513713A (ja) | 2024-03-27 |
| JP2024513713A5 true JP2024513713A5 (https=) | 2025-03-26 |
Family
ID=80937091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557116A Pending JP2024513713A (ja) | 2021-03-19 | 2022-03-17 | クローディン－３を標的とするキメラ抗原受容体および癌を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230192842A1 (https=) |
| EP (1) | EP4308605A1 (https=) |
| JP (1) | JP2024513713A (https=) |
| KR (1) | KR20230160307A (https=) |
| CN (2) | CN118638226A (https=) |
| AR (1) | AR125136A1 (https=) |
| BR (1) | BR112023018987A2 (https=) |
| CA (1) | CA3212615A1 (https=) |
| TW (1) | TW202304960A (https=) |
| WO (1) | WO2022195535A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240176948A (ko) * | 2023-06-15 | 2024-12-26 | 에이비온 주식회사 | 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| JP7098521B2 (ja) | 2015-11-24 | 2022-07-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | レトロウイルス産生のための安定な細胞株 |
| EP3380605A1 (en) | 2015-11-24 | 2018-10-03 | GlaxoSmithKline Intellectual Property Development Limited | Transient transfection method for retroviral production |
| KR102340989B1 (ko) * | 2018-03-28 | 2021-12-20 | 에이비온 주식회사 | 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도 |
| KR20210037581A (ko) * | 2019-09-26 | 2021-04-06 | (재)록원바이오융합연구재단 | 항-클라우딘-3 키메라 항원 수용체 |
-
2022
- 2022-03-17 CN CN202410502040.XA patent/CN118638226A/zh active Pending
- 2022-03-17 EP EP22712638.0A patent/EP4308605A1/en active Pending
- 2022-03-17 CN CN202280036179.9A patent/CN117377691A/zh active Pending
- 2022-03-17 KR KR1020237035622A patent/KR20230160307A/ko active Pending
- 2022-03-17 CA CA3212615A patent/CA3212615A1/en active Pending
- 2022-03-17 BR BR112023018987A patent/BR112023018987A2/pt unknown
- 2022-03-17 TW TW111109789A patent/TW202304960A/zh unknown
- 2022-03-17 WO PCT/IB2022/052443 patent/WO2022195535A1/en not_active Ceased
- 2022-03-17 AR ARP220100626A patent/AR125136A1/es not_active Application Discontinuation
- 2022-03-17 JP JP2023557116A patent/JP2024513713A/ja active Pending
- 2022-09-22 US US17/950,667 patent/US20230192842A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527409A5 (https=) | ||
| ES2801873T3 (es) | Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos | |
| AU2016347058B2 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection | |
| JP2018526028A5 (https=) | ||
| JP2025028239A5 (https=) | ||
| JP2022537159A5 (https=) | ||
| CN110831965A (zh) | 靶向hiv gp120和cd3的多特异性抗体 | |
| JP2024532485A5 (https=) | ||
| JP2021522162A5 (https=) | ||
| US20240052052A1 (en) | Novel anti-cd24 antibodies | |
| CN111148761A (zh) | 多特异性抗体及其制备和使用方法 | |
| IL271260B1 (en) | Multispecific antibodies and methods for their preparation and use | |
| WO2022152168A1 (zh) | 靶向ror1的抗体及其用途 | |
| JP2023539591A5 (https=) | ||
| JP2021535758A5 (https=) | ||
| IL271257B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| JP2024513713A5 (https=) | ||
| JP2021524451A (ja) | 最適化済みｇｐ４１結合分子及びその使用 | |
| CN114437214A (zh) | 靶向lir1的抗体及其用途 | |
| JP2025504398A5 (https=) | ||
| CN119546343A (zh) | 细胞因子融合蛋白与cd8抗原结合分子的组合 | |
| JP2022550120A5 (https=) | ||
| KR20260062933A (ko) | 항-γδ TCR 항체 및 이의 용도 | |
| WO2025232896A1 (zh) | 药物组合及用途 | |
| CN121752599A (zh) | 抗γδTCR抗体及其用途 |